FDA in­spec­tion of Chi­na-based site mak­ing Co­herus' po­ten­tial new can­cer drug ends with three ob­ser­va­tions

Af­ter Covid-re­lat­ed de­lays that forced the FDA to de­lay its Chi­na-based in­spec­tions, Co­herus Bio­Sciences said to­day that its Chi­na-based part­ner Jun­shi Bio­sciences has now suc­cess­ful­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER